Atopic Dermatitis: Generic Erosion Leads to Stagnant Market - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/342156

Atopic Dermatitis: Generic Erosion Leads to Stagnant Market

Description:

Atopic dermatitis is one of the largest segments of the dermatology disease market in terms of patient population. However, sales in this market are relative small, primarily because of generics competition. Symptomatic treatment of atopic dermatitis relies primarily on the use of topical formulations (corticosteroids and immunosuppressants). Physicians consider current oral treatments to have limited value in the treatment of atopic dermatitis; antihistamines are the primary class of oral agents used.

One of the key issues in the development of new treatments for this disease is the development of more-effective formulations that provide better delivery of either new or established agents to the affected parts of the skin. This report provides an overview of atopic dermatitis, including its symptoms, pathophysiology, and prevalence in the seven major markets we cover. We discuss the currently available treatments for atopic dermatitis and the emerging agents for the treatment of this disease, and we provide an analysis of the market out to 2010, including the role of emerging agents and the increasing presence of specialist companies.

Business Implications
Although atopic dermatitis is one of the most significant dermatology markets in terms of prevalence, sales in this indication are relatively small, accounting for $375 million in the seven major markets in 2005. The United States and Japan account for most of the revenues in the atopic dermatitis market, respectively generating $184 million and $102 million of the 2005 revenues in this market segment. The treatment of atopic dermatitis currently relies predominantly on three classes of agent: topical corticosteroids, topical immunosuppressants, and oral antihistamines, with the last principally used in Japan. Both the topical corticosteroid and antihistamine markets are highly fragmented, with a significant number of generic agents available.

The two topical immunosuppressants pimecrolimus (Novartis’s Elidel) and tacrolimus (Astellas's Protopic) are the leading branded products in this segment and, until 2005, were the market’s only significant growth drivers. They produced combined revenues of $133 million for the treatment of atopic dermatitis in 2005, with U.S. sales declining sharply in the past year because of the FDA’s imposition of a black box warning because of safety concerns. The impact of these safety concerns and the lack of innovative new therapeutics in latestage development for the treatment of atopic dermatitis will lead to a period of negligible revenue growth.
Only after 2010, if some of the new approaches in clinical development prove successful, is significant growth in the value of this market segment likely to occur. In the absence of such developments, revenues from this market segment will decline slightly.

Contents:

Introduction
An Overview of Atopic Dermatitis
Symptoms and Pathophysiology
Diagnosis
Prevalence
Current Treatments
Topical Corticosteroids
Topical Immunosuppressants
Antihistamines
Current Market
Drugs in Development
Connetics’s Desonide and Clobetasol Propionate
Arachnova’s AA-10006
Aerovance’s Pitrakinra
Anacor Pharmaceuticals’ AN-0128
Corgentech’s Avrina
Nucryst Pharmaceuticals’ NPI-32101
ProMetic Life Sciences’ rAAT and York Pharma’s Sabarep
Market Outlook

Figure 1 The Itch-Scratch Cycle in Atopic Dermatitis

Table 1 Prevalence of Atopic Dermatitis in the Major Pharmaceutical Markets, 2005 and 2010
Table 2 Sales of Select Therapies for the Treatment of Atopic Dermatitis in the Seven Major Markets, 2005
Table 3 Emerging Agents for the Treatment of Dermatitis, 2006

Companies Mentioned

Companies Mentioned Include: - Altana - Astellas - Arachnova - Aerovance - Anacor Pharmaceuticals - Connetics - Clobetasol - Corgentech - Daiichi Sankyo - Dainippon Sumitomo - Kyowa - Novartis - ProMetic Life Sciences - Pfizer - Schering-Plough - Sanofi-Aventis - UCB - York Pharma

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/342156

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 09/01/2009 04:35:09

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com

Order information

Please verify that the product information is correct and select the format you require.


Product Name:
Atopic Dermatitis: Generic Erosion Leads to Stagnant Market
Web Address:
http://www.researchandmarkets.com/reports/342156
Office Code:
OCIJEINMSOX

Report formats

Please enter the quantity of the report format you require.

	Format	Quantity	Price
	Electronic (PDF) - Single User		€1,114.00

Contact information

Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Page 2 of 2
Printed 09/01/2009 04:35:09

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder Name:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World